17/04/2014 00:17:50 Free Membership Login

Electro Optical Sciences News (NASDAQ:MELA)

DateTimeSource
Headline
04/09/20148:23AMBWMedical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind® system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook as Chief Financial Officer, filling the position which had been vacant since December 31, 2013... More...>>
03/17/20144:00PMBWMELA Sciences Announces 2013 Fourth Quarter and Year-End Financial Results
MELA Sciences, Inc. (NASDAQ:MELA), (the “Company”), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced financial results for the fourth quarter and year ended December 31, 2013. Conference Call The Company will host a conference... More...>>
03/14/20147:55AMBWOptical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the appointment of veteran medical device investment banker Samuel E. Navarro to the Board of Directors. Mr. Navarro’s appointment brings MELA’s Board... More...>>
03/11/201410:35AMMWUSMELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41 WEST HARRISON, NY--(Marketwired - Mar 11, 2014) - Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty... More...>>
03/06/20149:36AMBWDermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market’s close. MELA Sciences President and CEO, Rose Crane will host... More...>>
02/25/201411:03AMMWUSRose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Bus. Talk Radi...
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM Interview at 1:05 pm CST / 2:05 pm EST on The Traders Network Radio Show, Hosted by Michael Yorba DALLAS, TX and IRVINGTON, NY--(Marketwired - Feb 25, 2014) - MELA Sciences, Inc. (NASDAQ:... More...>>
02/24/20147:55AMBWMelanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The... More...>>
02/05/20145:15PMBWMELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common... More...>>
02/03/20147:55AMBWMelanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that... More...>>
01/31/20142:03PMBWCORRECTING & REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Instituti...
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.). The corrected release reads: MELANOMA DIAGNOSTIC PROVIDER, MELA SCIENCES, TO RAISE $12.45 MILLION IN PRIVATE PLACEMENT TO INSTITUTIONAL... More...>>
01/31/20149:44AMBWMelanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors & MELA S...
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the... More...>>
01/30/20147:55AMBWDermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
“This is the wave of the future for dermatology.” MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind® workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks... More...>>
01/27/20147:55AMBWMedical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC & to Exhibit at Maui Derm...
Presentation Audio and Slides Available Live and Via Webcast MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference... More...>>
01/22/20147:55AMBWMELA Sciences Announces the Results of its Third Clinical Advisory Meeting & the Four Clinical Posters Presented at the Winte...
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical... More...>>
01/16/20147:55AMBWMelanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinic...
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA-approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, will host its third company-sponsored Clinical Advisory meeting for select dermatologists and key opinion leaders in melanoma and provide recent clinical findings... More...>>
01/02/20148:00AMBWMELA Sciences Appoints Healthcare Executive Jeff O’Donnell as Director & Streamlines Board to Support Refocused Go-to-Marke...
Richard Steinhart Resigns as CFO MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced a realignment of its Board’s composition and size to better support the Company’s refocused go-to-market strategy... More...>>
12/09/201312:47PMBWMELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting & Mount Sina...
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist feedback from its second Clinical Advisory Meeting held in conjunction with the 16th Annual Mount Sinai Winter Dermatology... More...>>
12/06/20137:56AMBWMelanoma Diagnostics Leader, MELA Sciences, Inc., Participates in Skin Cancer Diagnostic Workshop with Leading German Dermato...
MELA Sciences, Inc. (NASDAQ:MELA), designer and developer of MelaFind®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists... More...>>
12/05/20137:56AMBWMelanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting Friday, Dec. 6th in Conjunction with Mount Sinai ...
MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, announces the Company will participate in the 16th Annual Mount Sinai Winter Dermatology Symposium in New York City, December... More...>>
11/06/20134:05PMGLOBEMELA Sciences, a Leader in Melanoma Diagnostics, Appoints Rose Crane as President and Chief Executive Officer and a Director,...
IRVINGTON, N.Y., Nov. 6, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, an optical diagnostic device using proprietary technology that enables dermatologists to "see" below the surface of a patient's skin to aid in the diagnosis... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq mela140417 00:17